Provided by Tiger Trade Technology Pte. Ltd.

IGC Pharma

0.2890
+0.01595.82%
Post-market: 0.2786-0.0104-3.60%19:55 EST
Volume:152.16K
Turnover:42.13K
Market Cap:27.47M
PE:-3.71
High:0.2890
Open:0.2705
Low:0.2702
Close:0.2731
52wk High:0.4985
52wk Low:0.2420
Shares:95.04M
Float Shares:87.50M
Volume Ratio:0.39
T/O Rate:0.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0780
EPS(LYR):-0.0931
ROE:-83.34%
ROA:-50.31%
PB:3.39
PE(LYR):-3.11

Loading ...

IGC Pharma Reaches 65% Enrollment in Phase 2 CALMA Trial for Alzheimer’s Agitation

Reuters
·
Dec 09, 2025

Press Release: NeoVolta Enters into Definitive Agreements Led by Infinite Grid Capital to Advance 2 GWh U.S. Battery Energy Storage System Manufacturing Initiative

Dow Jones
·
Nov 24, 2025

IGC Pharma Reports Progress Amid Financial Losses

TIPRANKS
·
Nov 18, 2025

IGC Pharma expects ‘continued strong momentum’ into 2H26

TIPRANKS
·
Nov 17, 2025

IGC Pharma Q2 EPS $(0.02), Inline, Sales $191.000K Miss $325.000K Estimate

Benzinga
·
Nov 17, 2025

IGC Pharma Sells Non-Core Facility for $2.7 Million

Reuters
·
Nov 17, 2025

IGC Pharma files to sell 978,235 shares of common stock for holders

TIPRANKS
·
Nov 17, 2025

IGC Pharma Reports Lower Revenue Amid Shift to Alzheimer’s Drug Development

Reuters
·
Nov 15, 2025

IGC Pharma Sells Vancouver Assets to Wellness Essentials

TIPRANKS
·
Nov 14, 2025

IGC Pharma Granted U.S. Patent for Novel Alzheimer's Drug Composition Targeting CNS Disorders

Reuters
·
Nov 13, 2025

IGC Pharma expands Phase 2 CALMA trial to University of South Florida

TIPRANKS
·
Oct 14, 2025

IGC Pharma Inc. Held Annual Meeting of Stockholders

Reuters
·
Oct 14, 2025

IGC Pharma announces in-vitro preclinical data for IGC-1C

TIPRANKS
·
Oct 07, 2025

IGC Pharma Announces Promising Preclinical Results for IGC-1C, a Novel Drug Candidate Targeting Tau Protein in Alzheimer’s Disease

Reuters
·
Oct 07, 2025

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

GlobeNewswire
·
Oct 06, 2025

IGC Pharma Subsidiary Signs Asset Sale Agreement

TIPRANKS
·
Oct 02, 2025

Corrected-IGC Pharma Inc - Unit Enters Sale of Assets Agreement for $2.7 Mln - SEC Filing (Adds Dropped Currency Symbol)

THOMSON REUTERS
·
Oct 02, 2025

BRIEF-IGC Pharma's Unit Enters Sale Of Assets Agreement For $2.7 Million - SEC Filing

Reuters
·
Oct 02, 2025

IGC Pharma Sells Holi Hemp Assets to Wellness Essentials Northwest in $2.7 Million Deal

Reuters
·
Oct 02, 2025

IGC Pharma expands CALMA Phase 2 trial with Ichor Research site

TIPRANKS
·
Sep 29, 2025